1. Heart diseases in pregnancy

2. Cardiovascular changes during pregnancy: intravascular volume and cardiac output increase by 50%  Decrease in peripheral vascular resistance and blood pressure (endothelium dependent factors)  Physiologic high output (HR 10-20 bpm and ejection fraction – early increase in ventricular wall muscle mass, increased end- diastolic volume, heart is phisiologicly dilatated and has higher contractility))  Peak during the second trimester (20-28)

3.  The increased blood volume serves two purposes. First, it facilitates maternal and fetal exchanges of respiratory gases, nutrients and metabolites. Second, it reduces the impact of maternal blood loss at delivery. Typical losses of 300-500 ml for vaginal births and 750-1000 ml for Caesarean sections are thus compensated with the so-called "autotransfusion" of blood from the contracting uterus  Aortocaval Compression - enlarged uterus compresses both the inferior vena cava and the lower aorta when the patient lies supine cousing reducton in return to the heart and cosequent fall in stroke volume and cardiac output (up to 25 %). Pregnant woment should lie on the side or the pelvis should be rotated - so the uterus drops on the side. Reduced cardiac uotput is associated with reduction in uterine blood flow, and lower placental perfusion = deceleration in FHR on CTG

4.  Pulmonary vascular resistance like systemic vascular resistance in diminished  PCWP – pulomary capillary wedge pressure is the same, but colloid oncotic pressure is reduced - making pregnant women susceptible to pulmonary oedema (espessialy if there is increse in cardiac pre- load - i.v. Fluides or increased in pulomnary capillary permeability - preeclampsia)

5. LABOUR:  Futher increase in cardiac uotput ( 15% in the first stage and 50 % in the second stage)  Uterine contractions lead to autotransfusion of 300 – 500 ml of blood into circulation  Sympathetic response to pain and anxiety elevates futher HR and blood pressure  After delivery there is immediate rise in cardiac output – relife of IVC and contracting uterus empties the blood to systemic circulation  Women with cardiovascular disease are most at risk of pulmonary oedema during second satge of labour and immediate postpartum period  Cardiac output returns to normal in 2 weeks.

6.  Symptoms mimicking cardiac disease in healthy pregnant women: fatigue, dyspnea, light-headedness  „Abnormal” cardiac findings in pregnancy: displaced apical impulse, prominent jugular venous pulsations, widely split I and II heart sounds, soft ejection systolic murmur  ECG findings: sinus tachycardia, premature atrial/ ventricular ectopic beats, right/left axis deviation, ST-segment depression, T-wave changes

7. Echocardiographic findings  Mild increase in left ventricular diastolic dimension with preservation of ejection fraction  Functional tricuspid and mitral regurgitation  Small pericardial effusion

8. Pathology

9. Outcomes vary with different cardiac lesions Ability to tolerate pregnancy depends on :  Precence of pulmonary hypertention  Functional class – NYHA  Heamodynamic significance of any lesion  Presence of cyyanosis (arterial oxygen sauration < 80%) High risk of death during pregnancy: Eisenmenger syndrome, pulmonary vascular obstructive disease, Marfan syndrome with aortopathy, mitral stenosis( pulmonary oedema)  Other complications: heart failure, arrythmias, stroke  Fetal complications: spontaneus abortion, premature birth, IUGR, low birth weight, intrauterine fetal death

10. Left-to-right cardiac shunts: atrial septal defect, ventricular septal defect, patent ductus arteriosus  The incidence of congenital heart disease in pregnancy is increasing - beter corresctive surgery in children  Higher cardiac output does not increase shunting becouse of attenuating effect of the decrease in peripheral vascular resistance  Pregnancy, labour and delivery – well tolerated unless pulmonary hypertension exists  Risk of paradoxical embolism! with atrial shunts (patent foramen ovale)

11. Aortic stenosis Left ventricular outflow tract obstruction  Heart failure / ischemia developement in severe stenosis (aortic valve area 64mmHg)  Hypertrophic and noncompliant left ventricle  Complications with severe stenosis because of restricted ability to increase cardiac output

12. Management:  Symptomatic aortic stenosis: surgical correction first! then pregnancy  Absence of symptoms does not guarantee good tolerance of pregnancy!  If necessary: baloon valvuloplasty during labor and delivery

13. Coarctation of the aorta  Associated with: bicuspid aortic valve, aneurysms of the circle of Willis, ventricular septal defects, Turner syndrome  Risk of aortic rupture in the III trimester and during labor if CoA not corrected  If CoA corrected before pregnancy – risk of PIH developement due to residual abnormalities in aortic complience

14. Pulmonary valve stenosis  Classification - according to the peak pressure gradient across the valve: mild 80mmHg  Pregnancy well tolerated if stenosis mild or treated by valvuloplasty or surgery  Right-sided heart failure or atrial arrhythmias in severe stenosis (including asymptomatic!)

15. Management:  Severe pulmonary valve stenosis requires correction before pregnancy  If symptoms progress during pregnancy – baloon valvuloplasty

16. Tetralogy of Fallot  If not corrected/palliated: - fall in systemic vascular resistance and rise in cardiac output exacerbate right-to-left shunting -results: increased maternal hypoxemia and cyanosis -poor fetal outcomes (loss rate ~30%) -maternal mortality risk 4 – 15%  If succesfully corrected: low risk; pregnancy well tolerated

17. Marfan syndrome  Connective tissue disorder  Autosomal-dominant  Complications due to medial aortopathy: dilation, dissection, valvular regurgitation  Aortic root replacement before pregnancy does not eliminate the risk of dissection of the residual native aorta!

18. Management  Recent data: maternal mortality rate: 1%; fetal mortality rate ~ 22%  Aortic root involvement: preconception counseling – risk in pregnancy  Little cardiovascular involvement; aortic root diameter < 40mm – good tolerance of pregnancy  Serial echocardiography to monitor for progressive aortic root dilation  Beta-blockers prophylactically – reduce aortic dilatation

19. Eisenmenger syndrome & pulmonary vascular obstructive disease  ES: pre-existing left-to-right shunt; pulmonary pressure rise to systemic level; shunt flow right- to-left  Pregnancy complications: at term and during 1st postpartum week  High frequency of: spontaneous abortion, IUGR, preterm labor

20.  Maternal mortality rate: primary pulmonary hypertention ~ 30%; Eisenmenger syndrome ~36%; secondary vascular pulmonary hypertention ~56%  Perinatal mortality due mainly to prematurity  Neonatal mortality rate: 12%  Preconception counseling: extreme risk from pregnancy; pregnancy is contraindicated!

21. Acquired heart disease - Mitral stenosis  The most common valvular lesion in pregnancy  Hypervolemia and tachycardia exacerbate transmitral gradient  Symptoms: asymtomatic, dyspnoea, cough  Even asymptomatic patients (mild to moderate stenosis) can develope atrial fibrillation and heart failure in antepartum/peripartum period! Pulmonary oedema.

22. Outcomes  No maternal mortality  Morbidity (heart failure and arrhytmias)  Risk of complications higher in patients with a history of cardiac events: arrhytmias, stroke, pulmonary oedema  Fetal/neonatal outcomes: risk increases with severity of mitral stenosis

23. Management  In patients in NYHA class III or IV (despite optimal medical therapy), percutaneous mitral valvuloplasty during pregnancy should be considered

24. Other rheumatic lesions  Rheumatic aortic stenosis: risk similar to congenital aortic stenosis  Aortic or mitral regurgitation – well tolerated during pregnancy  Function may deteriorate (NYHA classification)

25. Peripartum cardiomyopathy  Idiopathic dilated cardiomyopathy, involves ventricular systolic dysfunction that developes during the last month of pregnancy or in the first 5 months after delivery in patients with no known underlying disease  Heart failure – the most common manifestation; others: arrhytmias, embolic events

26.  Outcomes: improvement in NYHA functional status postpartum or persisting/worsening heart lesion  Relapse rate in subsequent pregnancy: - Substantial in women with persisting cardiac enlargement / left ventricular dysfunction - Possibility of persistent subclinical dysfunction (despite of recovered systolic function)

27. Atheromatous coronary artery disease  If possible – assessment (exercise testing) and treatment (coronary bypass surgery) before pregnancy  Risk in pregnancy: angina developement, myocardial infarction, especially in the peripartum period  Coronary angiography: recognition of mechanism of the infarct

28. Management  Thrombolytics shoul be avoided if coronary artery dissection occured  Percutaneous intervention (PCI) with stenting is optimal  Differentiate with: congenital coronary anomalies, disease with aneurysm formation, coronary arteriitis, autoimmune vascular diseases

29. Clinical approach - general recommendations: 1. Risk stratification 2. Antepartum management 3. Peripartum management 4. Recurrence of congenital lesion in the neonate 5. Site of antepartum and peripartum care

30. Risk assessment  Cardiovascular history and examination  12-lead electrocardiogram  Transthoracic electrocardiogram  Arterial oxygen saturation measurement by percutaneous oximetry in cyanotic patients  Define underlying cardiac lesion  Assess: ventricular function, pulmonary pressure, severity of obstructive lesions, persistence of shunts, hypoxemia

31. Low risk  Small left-to-right shunt  Repaired lesions without residual cardiac dysfunction  Isolated mitral valve prolapse without significant regurgitation  Bicuspid aortic valve without stenosis  Mild/moderate pulmonic stenosis  Valvular regurgitation with normal ventricular systolic function  Patient can be managed in a community hospital

32. High risk  Significant pulmonary hypertention  Marfan syndrome with aortic root or major valvular involvement  Peripartum cardiomyopathy with residual left ventricular systolic dysfunction  Patient should be managed in a high-risk pregnancy unit by a multidisciplinary team staffed by obstetricians, cardiologists, anesthesiologists and pediatricians

33. Antepartum management  Limiting activity in severely affected patients; hospital admission by mid-second trimester  Pregnancy complications: early identification, aggresive treatment (ie. PIH, hyperthyroidism, infections, anemia)  Mitral stenosis: rather beta-blockers than digoxin  Coarctation, Marfan syndrome, ascending aortopathy: empiric therapy with beta-blockers

34.  Arrhytmias: if possible, avoid drugs in the 1st trimester, but:  Drugs administration for patients with severe symptoms or poor tolerance of sustained arrhytmias  Antiarrhytmic drugs: preferred: digoxin, cardio-selective beta-blockers, adenosine; limited use: quinidine, sotalol, lidocaine, flecainide, propafenone; contraindicated: amiodarone  Electrical cardioversion is save  Implantable cardioverter-defibrillator

35. Anticoagulation therapy  Oral warfarin: non teratogenic in dose <5mg per day; risk of fetal intracranial bleeding throughout pregnancy, especially during vaginal delivery unless warfarin stopped before labor  Heparin: less effective in patients with prosthetic valves, safe for the fetus 6-12 Hbd  Low-molecular-weight heparin: more stable anticoagulation level  Low-dose aspirin in women with prosthetic valves as a part of antithrobotic regimen

36. Peripartum management  Elective cesarean section - indicated for: aortic dissection, Marfan syndrome with dilated aortic root, taking warfarin within 2 weeks of labour  Preterm planned induction: in high-risk patients to ensure that appropriate staff and equipment are avaliable; uncommon  Hemodynamic monitoring: no consensus on using invasive procedures during labor and delivery

37.  Replace anticoagulants by heparine at 36 Hbd  Give up heparin at least 12 hours before induction  Routine antibiotic prophylaxis for endocarditis: controversial in cesarean section or uncomplicated vaginal delivery; indicated in patients with prosthetic valves or previous endocarditis  Pain control: epidural anaesthesia and adequate volume preloading is recommended

38.  Positioning the patient on her left side lessens hemodynamic fluctuations associated with contractions  Forceps or vacuum extractor at the end of second stage to shorten delivery  Postpartum monitoring of patients at intermediate or high risk: for at least 72 hours

39. Risk of congenital heart disease in offspring  0.4 - 1% in general population  10 - fold increase if a first-degree relative is affected  Patients of reproductive age with congenital heart disease should be offered genetic assessment and counseling: estimation of transmission risk and information of the options for prenatal diagnosis